BEATcc (ENGOT-CX10/GEICO 68-C/JGOG-1084/GOG-3030): A randomized phase III trial of first-line atezolizumab with bevacizumab and platinum-based chemotherapy for metastatic (stage IVB), persistent, or recurrent cervical cancer

IF 4.5 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Gynecologic oncology Pub Date : 2024-10-09 DOI:10.1016/j.ygyno.2024.07.037

Ana Oaknin , Laurence Gladieff , Jerónimo Martínez-García , Guillermo Villacampa , Munetaka Takekuma , Ugo De Giorgi , Kristina Lindemann , Linn Woelber , Nicoletta Colombo , Linda Duska , Alexandra Leary , Ana Godoy Ortiz , Shin Nishio , Maria Jesús Rubio-Pérez , Satoshi Yamaguchi , Domenica Lorusso , Leslie Randall

引用次数: 0

查看原文本刊更多论文

BEATcc（ENGOT-CX10/GEICO 68-C/JGOG-1084/GOG-3030）：一线阿特珠单抗联合贝伐单抗和铂类化疗治疗转移性（IVB 期）、顽固性或复发性宫颈癌的随机 III 期试验

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gynecologic oncology 医学-妇产科学

CiteScore

8.60

自引率

6.40%

发文量

1062

审稿时长

37 days

期刊介绍： Gynecologic Oncology, an international journal, is devoted to the publication of clinical and investigative articles that concern tumors of the female reproductive tract. Investigations relating to the etiology, diagnosis, and treatment of female cancers, as well as research from any of the disciplines related to this field of interest, are published. Research Areas Include: • Cell and molecular biology • Chemotherapy • Cytology • Endocrinology • Epidemiology • Genetics • Gynecologic surgery • Immunology • Pathology • Radiotherapy